Sort by
Refine Your Search
-
the Laboratory of Nano Particles at Empa and also matriculate in ETH Zürich. The research focuses on developing innovative plasmonic materials. Surface plasmon resonance (SPR) and localized surface
-
% of the cases occur in developing countries, and most of these cases would be preventable with appropriate treatment. We are therefore developing an optically transparent, engineered corneal transplant
-
. Empa is a research institution of the ETH Domain. The Coating Technologies Group in Empa's Laboratory for Surface Science & Coating Technologies develops next-generation functional thin-films through
-
. Empa is a research institution of the ETH Domain. Our group focusses on the development of carbon-based (thermo)electric nanoscale devices and their application for quantum technologies and energy
-
how perishable biological products react inside cold chain unit operations and to pinpoint why some products decay faster. For that purpose, we develop digital twins of the cargo, based on measured air
-
. Utilizing a combination of experimental and computational approaches, we develop and characterize novel functional materials and devices driven by robust nanoscale quantum effects. We are currently seeking a
-
aiming to improve the management of infected wounds. Our group is focused on: i) Developing novel fluorescent-based detection approaches for the continuous monitoring of wound healing. ii) Achieving
-
at Empa in Dübendorf drives innovations in joining technologies and corrosion management to enable evolution towards increasingly efficient, reliable and sustainable material technologies. Joining
-
generation of hernia repair meshes with built-in local drug-delivery strategies to enhance post-surgical outcomes. Your tasks Develop novel medical liquid-core fibers for drug-loaded hernia repair meshes
-
. The acquired and already existing database will be used to further develop ML models for the automated detection of clinically relevant markers. The goal is to develop the technique towards potential clinical